AOC3, amine oxidase copper containing 3, 8639

N. diseases: 106; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0011853
Disease: Diabetes Mellitus, Experimental
Diabetes Mellitus, Experimental
0.500 Biomarker disease RGD Vascular adhesion protein-1 regulates leukocyte transmigration rate in the retina during diabetes. 19635478 2009
CUI: C0011853
Disease: Diabetes Mellitus, Experimental
Diabetes Mellitus, Experimental
0.500 Biomarker disease CTD_human Semicarbazide sensitive amine oxidase overexpression has dual consequences: insulin mimicry and diabetes-like complications. 14977883 2004
CUI: C0011853
Disease: Diabetes Mellitus, Experimental
Diabetes Mellitus, Experimental
0.500 Biomarker disease RGD Semicarbazide-sensitive amine oxidase activity in streptozotocin diabetic rats. 2218072 1990
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.390 AlteredExpression group BEFREE Serum vascular adhesion protein-1 is up-regulated in hyperglycemia and is associated with incident diabetes negatively. 30022055 2019
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.390 AlteredExpression group BEFREE A significantly decreased SSAO activity and plasma ET-1 level, as well as obviously increased plasma levels of MA and NO(x)- were observed in the DM + AG and DM + 2-BEA groups in comparison with the DM group (P < 0.01). 31182088 2019
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.390 Biomarker group BEFREE VAP-1 has been strongly implicated in several pathological processes, including diabetes, inflammation, hypertension, hepatic steatosis and renal diseases, and is an important disease marker and therapeutic target. 29364582 2018
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.390 Biomarker group BEFREE Vascular adhesion protein-1 (VAP-1) is secreted by vascular smooth muscle cells, adipocytes and endothelial cells with functional monoamine oxidase activity and is elevated in atherosclerosis, diabetes mellitus and obesity. 28044236 2017
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.390 Biomarker group CTD_human Elevation of SSAO activity is observed in atherosclerosis, diabetes mellitus and obesity. 23154672 2012
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.390 Biomarker group BEFREE The effect of interaction between SSAO and ACE in DM complication is of interest. 18413170 2009
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.390 AlteredExpression group BEFREE It is possible that the increased SSAO activity in diabetes may be a result of up-regulation due to increase of SSAO substrates, such as methylamine or aminoacetone. 16487546 2006
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.390 Biomarker group BEFREE Plasma SSAO correlated positively with duration of diabetes, HbA(1)c and plasma renin, and negatively with plasma angiotensinogen and body mass index. 15830186 2005
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.390 AlteredExpression group BEFREE The increased SSAO activity in diabetes is most likely dependent on post-transcriptional modifications or activation of existing inactive enzyme molecules. 15541390 2004
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus
0.390 Biomarker group BEFREE No wild-type animals displayed this phenotype.In conclusion, we suggest that this transgenic mouse model may be of great value for increasing the knowledge about to what extent human SSAO contributes to vascular complications in diabetes, and also to which extent inhibition of SSAO can prevent the development of such complications. 12686114 2003
CUI: C1561643
Disease: Chronic Kidney Diseases
Chronic Kidney Diseases
0.330 AlteredExpression group BEFREE Receiver-operating characteristic curve analyses demonstrated best performance for vascular adhesion protein-1 levels at 12 hours for acute kidney injury within 72 hours after surgery, especially in the subgroup of patients with chronic kidney disease (area under the receiver-operating characteristic curve, 0.78; P < .001). 31743166 2019
CUI: C1561643
Disease: Chronic Kidney Diseases
Chronic Kidney Diseases
0.330 AlteredExpression group BEFREE Receiver-operating characteristic curve analyses demonstrated best performance for vascular adhesion protein-1 levels at 12 hours for acute kidney injury within 72 hours after surgery, especially in the subgroup of patients with chronic kidney disease (area under the receiver-operating characteristic curve, 0.78; P < .001). 30633060 2019
CUI: C1561643
Disease: Chronic Kidney Diseases
Chronic Kidney Diseases
0.330 Biomarker group BEFREE The ALBUM trial investigated the efficacy of a novel, orally active inhibitor of vascular adhesion protein-1, ASP8232, compared with placebo for reducing albuminuria in individuals with type 2 diabetes and chronic kidney disease. 30413396 2018
CUI: C1561643
Disease: Chronic Kidney Diseases
Chronic Kidney Diseases
0.330 Biomarker group CTD_human VAP-1, a novel molecule linked to endothelial damage and kidney function in kidney allograft recipients. 23154672 2012
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.320 AlteredExpression group BEFREE We carried out a genomic-wide linkage scan for the quantitative trait locus of circulating VAP-1 levels in 1,100 Han Chinese individuals from 398 families in the Stanford Asian Pacific Program for Hypertension and Insulin Resistance study. 29364582 2018
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.320 Biomarker disease BEFREE Vascular adhesion protein-1 (VAP-1) is a promising therapeutic target for the treatment of diabetic nephropathy. 28601507 2017
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.320 Biomarker disease BEFREE Vascular adhesion protein-1 (VAP-1) is a promising therapeutic target for the treatment of diabetic nephropathy. 28988626 2017
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.320 Biomarker group CTD_human VAP-1, a novel molecule linked to endothelial damage and kidney function in kidney allograft recipients. 23154672 2012
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.320 Biomarker group BEFREE Plasma SSAO was higher in the group with late complications or hypertension, and in patients treated with ACE-inhibitors. 15830186 2005
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.320 Biomarker disease CTD_human Semicarbazide sensitive amine oxidase overexpression has dual consequences: insulin mimicry and diabetes-like complications. 14977883 2004
CUI: C0030524
Disease: Paratuberculosis
Paratuberculosis
0.300 Biomarker disease CTD_human Proteomic analysis of plasma from Holstein cows testing positive for Mycobacterium avium subsp. paratuberculosis (MAP). 22633222 2012
CUI: C0403447
Disease: Chronic Kidney Insufficiency
Chronic Kidney Insufficiency
0.300 Biomarker disease CTD_human VAP-1, a novel molecule linked to endothelial damage and kidney function in kidney allograft recipients. 23154672 2012